Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT01242488 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: CDP6038
BIOLOGICAL: CDP6038
BIOLOGICAL: CDP6038
BIOLOGICAL: Tocilizumab (Actemra or RoActemra)
BIOLOGICAL: CDP6038
BIOLOGICAL: CDP6038
BIOLOGICAL: CDP6038
OTHER: Placebo sc
OTHER: Placebo sc
OTHER: Placebo iv

Sponsor

UCB Pharma